Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06961955 · ClinicalTrials.gov registry record · Phase 2
5 vs. 9-day Course of Whole Breast Radiotherapy With Boost for Early-stage Breast Cancer
A Phase 2 study of Breast Cancer and Ductal Breast Carcinoma in Situ, sponsored by University of Utah.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 144
- Enrollment target
- 1
- Study location
NCT06961955 is a Phase 2 study of Breast Cancer and Ductal Breast Carcinoma in Situ that is actively recruiting participants, run by University of Utah. The registered enrollment target is 144 participants, below the 2,803-participant average among 1,224 other Breast Cancer trials with a reported enrollment target (95% lower). The trial reports 1 study location across 1 state.
The verdict
NCT06961955, a Phase 2 study of Breast Cancer and Ductal Breast Carcinoma in Situ, is actively recruiting participants, sponsored by University of Utah.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 144 participants
- Enrollment target
- 1
- Study location
Study Summary
The goal of this study is to evaluate 5 days vs. 9 days of whole breast radiation.
Conditions Studied
Interventions
- RADIATION Radiation Therapy
Study Locations (1)
Utah
- Huntsman Cancer Institute/University of Utah - Salt Lake City
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 144 participants |
| Start Date | 2025-05-21 |
| Est. Completion | 2033-05 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06961955
The ClinicalTrials.gov registry entry for NCT06961955 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 144 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 2,803-participant average among 1,224 other Breast Cancer trials with a reported enrollment target (95% lower). The listed sponsor is University of Utah, which has 818 total studies on file at ClinicalTrials.gov.
The record links to 3 conditions, with Breast Cancer appearing as the primary indexed condition, and to 1 intervention - of which Radiation Therapy is the first listed.
NCT06961955 reports 1 study location spanning 1 distinct geographic area - top geographies include Utah.
Frequently Asked Questions
What is clinical trial NCT06961955 about?
NCT06961955 is a clinical study titled "5 vs. 9-day Course of Whole Breast Radiotherapy With Boost for Early-stage Breast Cancer". The goal of this study is to evaluate 5 days vs. 9 days of whole breast radiation.
What is the current status of trial NCT06961955?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 144 participants. The study started on 2025-05-21. Estimated completion is 2033-05.
What conditions does trial NCT06961955 study?
This clinical trial studies the following conditions: Breast Cancer, Ductal Breast Carcinoma in Situ, Invasive Carcinoma of Breast.
What interventions are being tested in trial NCT06961955?
The interventions under investigation include: Radiation Therapy (RADIATION).
Who is sponsoring clinical trial NCT06961955?
This trial is sponsored by University of Utah, which has 818 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06961955 being conducted?
This trial has 1 study location across Utah. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Breast Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Sequencing Antibody Drug Conjugates in ER+/HER2 LOW/ULTRA LOW MBC
RECRUITING · Phase 2
-
The SAPPHO Study: Sequential Therapy With Curative Intent in de Novo HER2+ Metastatic Breast Cancer
RECRUITING · Phase 2
-
Sacituzumab Govitecan +/- Pembrolizumab in Metastatic TNBC
RECRUITING · Phase 2
-
Evaluation of Talazoparib, a PARP Inhibitor, in Patients With Somatic BRCA Mutant Metastatic Breast Cancer: Genotyping Based Clinical Trial
RECRUITING · Phase 2
-
Endocrine Treatment Alone for Elderly Patients With Estrogen Receptor Positive Operable Breast Cancer and Low Recurrence Score
RECRUITING · Phase 2
-
Precision Medicine in Action: Phase II Trial of Response Adaptive Ablative Pre-operative SPBI (RAPS) and Non-operative Sentinel Lymph Node Biopsy in Patients With Early-stage ER+ Breast Cancer: RAPS Trial
RECRUITING · Phase 2
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.